Linear <scp>IgA</scp> bullous dermatosis and elevated bullous interleukin‐6 levels: Responsive to treatment with <scp>Anti‐IL</scp>‐6 receptor monoclonals-Reference-Cited by-同舟云学术

Linear IgA bullous dermatosis and elevated bullous interleukin‐6 levels: Responsive to treatment with Anti‐IL‐6 receptor monoclonals

Published:2023-02 Issue:2 Volume:11 Page:
ISSN:2050-0904
Container-title:Clinical Case Reports
language:en
Short-container-title:Clinical Case Reports

Author:

Jordan Stanley C.¹²^ORCID,Balzer Bonnie³,Nast Cynthia³,Atienza Janet¹,Lim Katherine¹,Kumar Sanjeev¹,Nissen Nicholas¹,Shin Bongha¹²

Affiliation:

1. Comprehensive Transplant Center Cedars‐Sinai Medical Center Los Angeles California USA

2. Transplantation & Immunology Laboratory Cedars‐Sinai Medical Center Los Angeles California USA

3. Department of Pathology & Laboratory Medicine Cedars‐Sinai Medical Center Los Angeles California USA

Abstract

AbstractLinear IgA bullous dermatosis (LABD) is a rare autoimmune/inflammatory skin condition. Here, we report on a patient who developed treatment resistant LABD. At diagnosis, elevations of IL‐6 and C‐reactive protein in the blood and extreme elevations of IL‐6 in LABD bullous fluid were seen. The patient responded well to tocilizumab (anti‐IL‐6 receptor) treatment.

Publisher

Wiley

Subject

General Medicine

Link

https://onlinelibrary.wiley.com/doi/pdf/10.1002/ccr3.6998

Reference9 articles.

1. Mechanisms and pathologic significances in increase in serum interleukin-6 (IL-6) and soluble IL-6 receptor after administration of an anti–IL-6 receptor antibody, tocilizumab, in patients with rheumatoid arthritis and Castleman disease

2. TNFalpha and IL-6 are mediators in the blistering process of pemphigus

3. Analysis of Serum Cytokine Profile in Pemphigus

Cited by 1 articles. 订阅此论文施引文献订阅此论文施引文献，注册后可以免费订阅5篇论文的施引文献，订阅后可以查看论文全部施引文献

1. Tofacitinib for the treatment of severe rare skin diseases: a narrative review;European Journal of Clinical Pharmacology;2024-01-17